BRPI0607739A2 - derivados de tetraidroindolona e tetraidroindazolona, composição compreendendo os mesmos e uso relacionado - Google Patents
derivados de tetraidroindolona e tetraidroindazolona, composição compreendendo os mesmos e uso relacionadoInfo
- Publication number
- BRPI0607739A2 BRPI0607739A2 BRPI0607739-0A BRPI0607739A BRPI0607739A2 BR PI0607739 A2 BRPI0607739 A2 BR PI0607739A2 BR PI0607739 A BRPI0607739 A BR PI0607739A BR PI0607739 A2 BRPI0607739 A2 BR PI0607739A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- composition
- tetrahydroindolone
- related use
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
DERIVADOS DE TETRAIDROINDOLONA E TETRAIDROINDAZOLONA, COMPOSIçãO COMPREENDENDO OS MESMOS E USO RELACIONADO. A presente invenção refere-se a compostos e sais farmaceuticamente aceitáveis da Fórmula 1: em que R~ 1~, R~ 2~, R~ 3~, R~ 4~, R~ 5~, R~ 6~, R~ 7~, n, Q1, Q2, Q3, Y, e X~ 1~-X~ 4~ são como definidos aqui. Compostos da fórmula I são úteis no tratamento de doenças e/ou condições relacionadas à proliferação celular, como câncer, inflamação, artrite, angiogênese, ou outras. Também refere-se a composições farmacêuticas compreendendo os compostos da invenção e métodos de tratar as condições acima mencionadas usando tais compostos.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65623005P | 2005-02-25 | 2005-02-25 | |
US70571505P | 2005-08-04 | 2005-08-04 | |
US72796505P | 2005-10-18 | 2005-10-18 | |
PCT/US2006/006988 WO2006091963A1 (en) | 2005-02-25 | 2006-02-27 | Tetrahydroindolone and tetrahydroindazolone derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0607739A2 true BRPI0607739A2 (pt) | 2009-09-29 |
Family
ID=36581601
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0607739-0A BRPI0607739A2 (pt) | 2005-02-25 | 2006-02-27 | derivados de tetraidroindolona e tetraidroindazolona, composição compreendendo os mesmos e uso relacionado |
Country Status (25)
Country | Link |
---|---|
US (8) | US7358370B2 (pt) |
EP (2) | EP1856057B1 (pt) |
JP (1) | JP4377942B2 (pt) |
KR (3) | KR20070114763A (pt) |
CN (1) | CN101180275B (pt) |
AR (1) | AR054186A1 (pt) |
AU (2) | AU2006216441B2 (pt) |
BR (1) | BRPI0607739A2 (pt) |
CA (1) | CA2598993C (pt) |
DK (1) | DK1856057T3 (pt) |
EA (1) | EA013521B1 (pt) |
ES (1) | ES2527770T3 (pt) |
GE (1) | GEP20104994B (pt) |
HK (1) | HK1117535A1 (pt) |
IL (1) | IL185280A (pt) |
MA (1) | MA29713B1 (pt) |
MX (1) | MX2007010227A (pt) |
NO (1) | NO20074274L (pt) |
NZ (2) | NZ560685A (pt) |
PL (1) | PL1856057T3 (pt) |
PT (1) | PT1856057E (pt) |
SI (1) | SI1856057T1 (pt) |
TW (1) | TWI382015B (pt) |
UA (1) | UA92907C2 (pt) |
WO (1) | WO2006091963A1 (pt) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005294404A1 (en) * | 2004-10-04 | 2006-04-20 | Myriad Genetics, Inc. | Compounds for Alzheimer's disease |
NZ560685A (en) * | 2005-02-25 | 2010-12-24 | Serenex Inc | Tetrahydroindolone and Tetrahydroindazolone derivatives |
ATE505468T1 (de) | 2005-06-27 | 2011-04-15 | Bristol Myers Squibb Co | N-gebundene heterocyclische antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden |
WO2007101156A1 (en) * | 2006-02-27 | 2007-09-07 | Serenex, Inc. | Cyclohexylamino, benzene, pyridine, and pyridazine derivatives |
EP2004614B1 (en) * | 2006-04-13 | 2016-10-19 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Tetrahalogenated compounds useful as inhibitors of angiogenesis |
US7595401B2 (en) | 2006-05-12 | 2009-09-29 | Myriad Pharmaceuticals, Inc. | Therapeutic compounds and their use in cancer |
KR20090018972A (ko) * | 2006-05-19 | 2009-02-24 | 아보트 러보러터리즈 | Cns 활성 융합된 비사이클로헤테로사이클 치환된 아자비사이클릭 알칸 유도체 |
ES2645095T3 (es) * | 2006-06-30 | 2017-12-04 | Sloan-Kettering Institute For Cancer Research | Tratamiento de enfermedades neurodegenerativas a través de la inhibición de Hsp90 |
US20080070918A1 (en) * | 2006-08-24 | 2008-03-20 | Huang Kenneth H | Dihydropyridazine, Tetrahydropyridine, Chromanone, and Dihydronaphthalenone Derivatives |
WO2008024981A1 (en) * | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Piperazine-substituted benzothiophenes for treatment of mental disorders |
US20090093452A1 (en) * | 2006-08-24 | 2009-04-09 | Pfizer Inc. | Pyrrole, Thiophene, Furan, Imidazole, Oxazole, and Thiazole Derivatives |
JP2010501593A (ja) * | 2006-08-24 | 2010-01-21 | セレネックス, インコーポレイテッド | イソキノリン、キナゾリンおよびフタラジン誘導体 |
WO2008024970A2 (en) * | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Tetrahydroindolone and tetrahydroindazolone derivatives |
WO2008024963A1 (en) * | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Benzene, pyridine, and pyridazine derivatives |
US20080119457A1 (en) * | 2006-08-24 | 2008-05-22 | Serenex, Inc. | Benzene, Pyridine, and Pyridazine Derivatives |
FR2907453B1 (fr) | 2006-10-24 | 2008-12-26 | Sanofi Aventis Sa | Nouveaux derives du fluorene,compositions les contenant et utilisation |
WO2008057246A2 (en) * | 2006-10-26 | 2008-05-15 | Synta Pharmaceuticals Corp. | Method for treating inflammatory disorders |
CN101273991B (zh) * | 2007-03-28 | 2010-05-26 | 广东同德药业有限公司 | 四氢吲哚酮/四氢吲唑酮/四氢咔唑衍生物及其盐在制备抗病毒药物中的应用 |
EP2146967A2 (en) * | 2007-04-16 | 2010-01-27 | Serenex, Inc. | Tetrahydroindole and tetrahydroindazole derivatives |
EP1997805A1 (en) * | 2007-06-01 | 2008-12-03 | Commissariat à l'Energie Atomique | Compounds with antiparasitic activity, applications thereof to the treatment of infectious diseases caused by apicomplexans |
EP2202223B1 (en) | 2007-10-18 | 2017-01-25 | Takeda Pharmaceutical Company Limited | Heterocyclic compound as blood rbp4 lowering agent |
FR2955323B1 (fr) * | 2010-01-19 | 2015-01-16 | Sanofi Aventis | Nouveaux derives d'indazole inhibiteurs d'hsp90, compositions les contenant et utilisation |
FR2943341B1 (fr) * | 2009-03-19 | 2011-03-11 | Sanofi Aventis | Nouveaux derives d'indazole inhibiteurs d'hsp90,compositions les contenant et utilisation |
MX2011009806A (es) * | 2009-03-19 | 2011-09-29 | Sanofi Sa | Nuevos derivados de indazol inhibidores de hsp90, composiciones que los contienen y su uso. |
ES2635494T3 (es) * | 2009-03-30 | 2017-10-04 | Nordic Bioscience A/S | Ensayo de biomarcador de fibrosis |
AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
US9205086B2 (en) | 2010-04-19 | 2015-12-08 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor |
CN101872359B (zh) * | 2010-06-11 | 2013-08-14 | 北京邮电大学 | 实现演变点发现的社会网络演化分析方法及*** |
GB201009853D0 (en) | 2010-06-11 | 2010-07-21 | Chroma Therapeutics Ltd | HSP90 inhibitors |
CN102311389A (zh) * | 2010-06-29 | 2012-01-11 | 王小龙 | 一种氮芳香取代吡唑衍生物、及其合成和抗癌应用 |
CN101967125B (zh) | 2010-10-08 | 2012-07-04 | 广州暨南生物医药研究开发基地有限公司 | 一种Hsp90抑制剂Xbj-B16-1及其制备方法与应用 |
CN101955461B (zh) * | 2010-10-08 | 2012-11-21 | 广州暨南生物医药研究开发基地有限公司 | 一种Hsp90抑制剂Xbj-B11及其制备方法与应用 |
BR112013023452A2 (pt) | 2011-03-15 | 2016-12-06 | Univ British Columbia | combinação de oligonucleotídeo anti-clusterina com inibidor de hsp90 para o tratamento de câncer de próstata |
CN102675288B (zh) * | 2011-03-18 | 2014-01-01 | 北京师范大学 | 2-((2-(双(2-吡啶甲基)氨基)乙基)氨基)-4-(3,6,6-三甲基-4-氧-4,5,6,7-四氢吲唑基)苯甲酰胺及制备、应用 |
AU2012332421A1 (en) | 2011-11-02 | 2014-06-05 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of Hsp90 inhibitors with topoisomerase I inhibitors |
CA2853806C (en) | 2011-11-02 | 2020-07-14 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with platinum-containing agents |
WO2013074594A1 (en) | 2011-11-14 | 2013-05-23 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with braf inhibitors |
WO2014025395A1 (en) | 2012-08-06 | 2014-02-13 | Duke University | Compounds and methods for targeting hsp90 |
CN103467356B (zh) * | 2013-08-12 | 2015-04-01 | 绍兴文理学院 | 一种四氢吲哚化合物及其制备方法与应用 |
MY194204A (en) | 2014-08-04 | 2022-11-21 | Nuevolution As | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
WO2016040809A1 (en) * | 2014-09-11 | 2016-03-17 | Esanex, Inc. | Indazolyl- and indolyl-benzamide derivatives |
WO2016086153A2 (en) | 2014-11-26 | 2016-06-02 | Esanex, Inc. | Use of tetrahydro!ndazolylbeimzamide and tetrahydroindolylbenzamide derivatives for the treatment of human immunodeficiency virus (hiv) and acquired immune deficiency syndrome (aids) |
CN104592203A (zh) * | 2015-01-30 | 2015-05-06 | 广州暨南生物医药研究开发基地有限公司 | 一种2-氨基-4-四氢吲唑取代的苯甲酰胺化合物及其在制备抗肿瘤药物中的应用 |
CN104592230B (zh) * | 2015-01-30 | 2017-02-01 | 广州暨南生物医药研究开发基地有限公司 | 一种2‑(石榴皮烷‑3‑氨基)‑4‑四氢吲唑取代的苯甲酰胺化合物及其应用 |
WO2016191412A1 (en) * | 2015-05-26 | 2016-12-01 | University Of South Florida | Antimicrobial compositions, methods of use, and methods of treatment of infections |
WO2017059434A1 (en) | 2015-10-02 | 2017-04-06 | Esanex, Inc. | Use of tetrahydroindazolylbenzamide and tetrahydroindolylbenzamide derivatives for the treatment of cancer |
JP6488402B2 (ja) * | 2015-10-13 | 2019-03-20 | 日本農薬株式会社 | オキシム基を有する縮合複素環化合物又はその塩類及び該化合物を含有する農園芸用殺虫剤並びにその使用方法 |
US11261187B2 (en) | 2016-04-22 | 2022-03-01 | Duke University | Compounds and methods for targeting HSP90 |
AU2017268356A1 (en) * | 2016-05-18 | 2018-11-15 | Esanex, Inc. | Combination therapies using indazolylbenzamide derivatives for the treatment of cancer |
US20190269656A1 (en) | 2016-09-23 | 2019-09-05 | Esanex, Inc. | Combination Therapies Using Indazolylbenzamide Derivatives for the Treatment of Cancer |
NZ748072A (en) | 2017-03-20 | 2020-06-26 | Forma Therapeutics Inc | Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators |
WO2020061255A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
MA53668A (fr) | 2018-09-19 | 2021-09-15 | Forma Therapeutics Inc | Traitement de la drépanocytose avec un composé activant la pyruvate kinase r |
MX2022007265A (es) | 2019-12-20 | 2022-09-09 | Nuevolution As | Compuestos activos frente a receptores nucleares. |
EP4126875A1 (en) | 2020-03-31 | 2023-02-08 | Nuevolution A/S | Compounds active towards nuclear receptors |
MX2022012260A (es) | 2020-03-31 | 2022-11-30 | Nuevolution As | Compuestos activos frente a receptores nucleares. |
CN114213332B (zh) * | 2022-02-21 | 2022-05-17 | 深圳市人民医院 | 一种四氢吲唑类化合物及其制备方法和应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4024862A1 (de) * | 1990-08-04 | 1992-02-13 | Hoechst Ag | 4,5,6,7-tetrahydro-3-aryl-indazole, verfahren zu ihrer herstellung und ihre verwendung als herbizide |
GB9812038D0 (en) | 1998-06-04 | 1998-07-29 | Merck Sharp & Dohme | Therapeutic compound |
GB9900222D0 (en) * | 1999-01-06 | 1999-02-24 | Merck Sharp & Dohme | Therapeutic compounds |
GB9911053D0 (en) * | 1999-05-12 | 1999-07-14 | Pharmacia & Upjohn Spa | 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents |
MXPA03001951A (es) * | 2000-09-06 | 2003-10-15 | Neurogen Corp | Pirroliminas y pirazoliminas fusionadas substituidas. |
EP1431267A4 (en) | 2001-08-09 | 2004-12-22 | Ono Pharmaceutical Co | COMPOUNDS DERIVED FROM CARBOXYLIC ACID AND MEDICAMENTS COMPRISING SUCH COMPOUNDS AS ACTIVE INGREDIENT |
DE10148618B4 (de) * | 2001-09-25 | 2007-05-03 | Schering Ag | Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel |
US20040180889A1 (en) * | 2002-03-01 | 2004-09-16 | Pintex Pharmaceuticals, Inc. | Pin1-modulating compounds and methods of use thereof |
US7759336B2 (en) | 2002-12-10 | 2010-07-20 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic compounds and medicinal use thereof |
PE20040804A1 (es) | 2002-12-19 | 2004-12-31 | Boehringer Ingelheim Pharma | DERIVADOS DE CARBOXAMIDAS COMO INHIBIDORES DEL FACTOR Xa |
NZ560685A (en) * | 2005-02-25 | 2010-12-24 | Serenex Inc | Tetrahydroindolone and Tetrahydroindazolone derivatives |
WO2006109846A1 (ja) | 2005-04-06 | 2006-10-19 | Takeda Pharmaceutical Company Limited | トリアゾール誘導体およびその用途 |
EP2146967A2 (en) * | 2007-04-16 | 2010-01-27 | Serenex, Inc. | Tetrahydroindole and tetrahydroindazole derivatives |
-
2006
- 2006-02-27 NZ NZ560685A patent/NZ560685A/en not_active IP Right Cessation
- 2006-02-27 CN CN200680010486.0A patent/CN101180275B/zh not_active Expired - Fee Related
- 2006-02-27 CA CA2598993A patent/CA2598993C/en active Active
- 2006-02-27 US US11/363,449 patent/US7358370B2/en active Active
- 2006-02-27 KR KR1020077021820A patent/KR20070114763A/ko not_active Application Discontinuation
- 2006-02-27 GE GEAP200610280A patent/GEP20104994B/en unknown
- 2006-02-27 BR BRPI0607739-0A patent/BRPI0607739A2/pt not_active Application Discontinuation
- 2006-02-27 ES ES06736330.9T patent/ES2527770T3/es active Active
- 2006-02-27 SI SI200631875T patent/SI1856057T1/sl unknown
- 2006-02-27 PL PL06736330T patent/PL1856057T3/pl unknown
- 2006-02-27 KR KR1020157005119A patent/KR20150029766A/ko active IP Right Grant
- 2006-02-27 EP EP06736330.9A patent/EP1856057B1/en active Active
- 2006-02-27 NZ NZ588960A patent/NZ588960A/en not_active IP Right Cessation
- 2006-02-27 MX MX2007010227A patent/MX2007010227A/es active IP Right Grant
- 2006-02-27 AR ARP060100720A patent/AR054186A1/es not_active Application Discontinuation
- 2006-02-27 EA EA200701808A patent/EA013521B1/ru not_active IP Right Cessation
- 2006-02-27 PT PT67363309T patent/PT1856057E/pt unknown
- 2006-02-27 AU AU2006216441A patent/AU2006216441B2/en not_active Ceased
- 2006-02-27 EP EP11173186.5A patent/EP2380879B1/en active Active
- 2006-02-27 DK DK06736330.9T patent/DK1856057T3/en active
- 2006-02-27 JP JP2007557244A patent/JP4377942B2/ja not_active Expired - Fee Related
- 2006-02-27 KR KR1020137020400A patent/KR101617774B1/ko active IP Right Grant
- 2006-02-27 WO PCT/US2006/006988 patent/WO2006091963A1/en active Application Filing
- 2006-02-27 TW TW095106716A patent/TWI382015B/zh not_active IP Right Cessation
- 2006-02-27 UA UAA200710606A patent/UA92907C2/uk unknown
-
2007
- 2007-08-14 IL IL185280A patent/IL185280A/en not_active IP Right Cessation
- 2007-08-22 NO NO20074274A patent/NO20074274L/no not_active Application Discontinuation
- 2007-09-11 MA MA30216A patent/MA29713B1/fr unknown
- 2007-12-19 US US11/959,784 patent/US7906529B2/en not_active Expired - Fee Related
-
2008
- 2008-11-07 HK HK08112229.0A patent/HK1117535A1/xx not_active IP Right Cessation
-
2010
- 2010-10-19 US US12/907,571 patent/US7928135B2/en active Active
-
2011
- 2011-04-07 US US13/081,637 patent/US8309548B2/en not_active Expired - Fee Related
- 2011-04-15 AU AU2011201700A patent/AU2011201700B2/en not_active Ceased
-
2012
- 2012-11-05 US US13/669,016 patent/US20130137686A1/en not_active Abandoned
-
2014
- 2014-08-04 US US14/451,033 patent/US9656956B2/en active Active
-
2017
- 2017-05-22 US US15/601,428 patent/US20170260174A1/en not_active Abandoned
-
2019
- 2019-05-10 US US16/408,959 patent/US20200071308A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0607739A2 (pt) | derivados de tetraidroindolona e tetraidroindazolona, composição compreendendo os mesmos e uso relacionado | |
BRPI0511132A (pt) | derivados de pirimidina e composição farmacêutica compreendendo os mesmos | |
SV1999000047A (es) | Nuevas dihidropirimidinas fef. lea 32792-sv | |
NO20085176L (no) | Fenyl substituerte heteroaryl-derivater og andvendelse som anti-tumor agenter | |
BRPI0618479A2 (pt) | pirrolpiridinas composição farmacêutica que as contém | |
BRPI0612125A2 (pt) | compostos da fórmula (i), processo para a fabricação destes, composto da fórmula iiia, composições farmacêuticas, método para o tratamento e/ou profilaxia de doenças associadas à modulação dos receptores cb1 e uso de compostos | |
BRPI0313942C1 (pt) | derivados de benzimidazol úteis como agentes antiproliferativos, seus processos de preparação, composição farmacêutica compreendendo os mesmos e usos dos referidos compostos nas preparações de composições farmacêuticas | |
UY30183A1 (es) | Derivados de quinolina | |
BRPI0716171B8 (pt) | composto, composição farmacêutica e uso de um composto | |
CY1113114T1 (el) | Αναστολεις των ενζυμων ενεργοποιησης ε1 | |
NO20070339L (no) | 1-aza-bicyklo[3 3.1]nonaner | |
BRPI0809977A8 (pt) | Uso de um composto, compostos e composição farmacêutica que o contém | |
BR0309343A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas | |
SE0202133D0 (sv) | Novel compounds | |
BR112012008849A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
BR0309342A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas | |
WO2007035620A3 (en) | Carbazole derivatives | |
BRPI0413151A (pt) | derivados de amino propanol | |
NO20054340L (no) | Nye sammenkoplede heterocykler og deres anvendelse | |
BRPI0514126A (pt) | derivados de naftiridina 2,8-dissubstituìdos | |
ECSP099425A (es) | Derivados de amina y su uso en enfermedades mediadas por el adrenorecetor beta 2 | |
BRPI0720742B8 (pt) | derivados de heteroaril pirrolidinil e piperidinil cetona, seus usos e composição farmacêutica compreendo os mesmos | |
SE0303541D0 (sv) | New compounds | |
DK1869038T3 (da) | Substituerede 5,6,7,8-tetrahydro-imidazol[1,2-a]pyridin-2-ylamin-forbindelser og deres anvendelse til fremstilling af lægemidler | |
BR0314363A (pt) | Indóis 2,4-substituìdos e seu uso como moduladores de 5-ht6 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |